Department of Pharmacology, School of Medicine, Vanderbilt University, Nashville, Tennessee, USA; email:
College of Pharmacy, Kyung Hee University, Seoul, Republic of Korea.
Annu Rev Med. 2024 Jan 29;75:129-143. doi: 10.1146/annurev-med-051322-120608. Epub 2023 Sep 20.
Major depressive disorder (MDD) is a leading cause of suicide in the world. Monoamine-based antidepressant drugs are a primary line of treatment for this mental disorder, although the delayed response and incomplete efficacy in some patients highlight the need for improved therapeutic approaches. Over the past two decades, ketamine has shown rapid onset with sustained (up to several days) antidepressant effects in patients whose MDD has not responded to conventional antidepressant drugs. Recent preclinical studies have started to elucidate the underlying mechanisms of ketamine's antidepressant properties. Herein, we describe and compare recent clinical and preclinical findings to provide a broad perspective of the relevant mechanisms for the antidepressant action of ketamine.
重度抑郁症(MDD)是世界范围内导致自杀的主要原因。单胺类抗抑郁药是治疗这种精神障碍的主要方法,尽管在一些患者中反应迟缓且疗效不完整,突出了需要改进治疗方法。在过去的二十年中,氯胺酮在对传统抗抑郁药治疗无反应的 MDD 患者中显示出快速起效和持续(长达数天)的抗抑郁作用。最近的临床前研究开始阐明氯胺酮抗抑郁特性的潜在机制。在此,我们描述并比较了最近的临床和临床前发现,为氯胺酮抗抑郁作用的相关机制提供了广泛的视角。